Revance Therapeutics, Inc. (RVNC)
RVNC moved a median of 0.00% 30 minutes after news, and -0.05% by the close. How RVNC actually reacts to news — the realized, point-in-time move the market made, measured across 701 labeled events over the last three years with zero look-ahead.
RVNC’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 44% | 466 |
| 30-min | 0.00% | 42% | 468 |
| 60-min | 0.00% | 41% | 468 |
| to close | -0.05% | 40% | 468 |
| Middle 50% of RVNC reactions | -0.51% to +0.20% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 701 |
Half of all Revance Therapeutics, Inc. news events land between -0.51% and +0.20% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How RVNC reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 20 | 0.00% | 45% | +0.30% |
| Coverage initiations | 23 | +0.13% | 57% | 0.00% |
| Rating reiterations | 37 | +0.17% | 65% | +0.30% |
| Price-target cuts | 19 | +0.33% | 63% | +0.17% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how RVNC ranks against every other measured name →
That’s how RVNC usually reacts — get an email when it moves on news →Email me when RVNC moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RVNC's baseline. Nothing else.
Recent RVNC events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 15-12G Revance Therapeutics, | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Form POSASR Revance Therapeutics, | SEC filing · Form POSASR | SEC EDGAR | — | — | |
| Form S-8 POS Revance Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Crown Laboratories Completes Acquisition of Revance Therapeutics | Press release | Business Wire | — | — | |
| Crown Laboratories Announces Completion of Acquisition of Revance Therapeutics | Press release | PR Newswire | — | — | |
| Form 8-K Revance Therapeutics, For: Feb 06 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer | Press release | PR Newswire | +0.14% | +0.00% | |
| Revance Stockholders Urged to Tender Their Shares in Support of Crown Transaction by the February 4th Deadline | Press release | PR Newswire | +0.14% | +0.00% | |
| Crown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.65 per Share and Extend Existing Tender Offer | Press release | Business Wire | +0.14% | +0.82% | |
| Form 8-K Revance Therapeutics, For: Jan 17 | SEC filing · Form 8-K | SEC EDGAR | +0.14% | +0.82% | |
| Crown Laboratories Extension of Tender Offer to Acquire Revance Therapeutics, Inc. | Press release | PR Newswire | +0.00% | -1.20% | |
| Cohen Milstein Urges Shareholders Who Lost Significant Money In Revance Therapeutics, Inc. To Contact Firm | Press release | Accesswire | -2.10% | -2.40% | |
| Teoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in Cash | Press release | PR Newswire | +2.42% | -1.14% | |
| Crown Laboratories Commences Friendly Tender Offer for All Outstanding Common Shares of Revance Therapeutics at $3.10 per share | Press release | PR Newswire | -0.01% | +0.00% | |
| Form 8-K Revance Therapeutics, For: Dec 11 | SEC filing · Form 8-K | SEC EDGAR | -0.01% | +0.00% | |
| Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement | Press release | Business Wire | -0.54% | -0.33% | |
| Form 8-K Revance Therapeutics, For: Dec 07 | SEC filing · Form 8-K | SEC EDGAR | -0.54% | -0.33% | |
| Form 8-K Revance Therapeutics, For: Dec 05 | SEC filing · Form 8-K | SEC EDGAR | +0.77% | -1.55% | |
| Form 8-K Revance Therapeutics, For: Dec 03 | SEC filing · Form 8-K | SEC EDGAR | +4.49% | +0.51% | |
| Form 8-K Revance Therapeutics, For: Nov 29 | SEC filing · Form 8-K | SEC EDGAR | +3.41% | -1.64% | |
| Form 8-K Revance Therapeutics, For: Nov 26 | SEC filing · Form 8-K | SEC EDGAR | +0.25% | +1.26% | |
| Form 8-K Revance Therapeutics, For: Nov 19 | SEC filing · Form 8-K | SEC EDGAR | -4.08% | -3.06% | |
| Form 8-K Revance Therapeutics, For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | +3.00% | +8.83% | |
| Form 10-Q Revance Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.95% | -12.53% | |
| Form 8-K Revance Therapeutics, For: Nov 07 | SEC filing · Form 8-K | SEC EDGAR | -0.95% | -12.53% | |
| Revance Reports Third Quarter 2024 Financial Results, Provides Corporate Update | Press release | Business Wire | -0.95% | -12.53% | |
| Form 8-K Revance Therapeutics, For: Nov 01 | SEC filing · Form 8-K | SEC EDGAR | -4.42% | -1.36% | |
| Form 8-K Revance Therapeutics, For: Oct 24 | SEC filing · Form 8-K | SEC EDGAR | -0.50% | -1.67% | |
| Form 8-K Revance Therapeutics, For: Oct 18 | SEC filing · Form 8-K | SEC EDGAR | +0.19% | +1.54% | |
| Form 8-K Revance Therapeutics, For: Oct 03 | SEC filing · Form 8-K | SEC EDGAR | +0.19% | -0.57% | |
| Form 8-K Revance Therapeutics, For: Sep 19 | SEC filing · Form 8-K | SEC EDGAR | +1.26% | +4.38% | |
| Form 8-K Revance Therapeutics, For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Form 8-K Revance Therapeutics, For: Aug 27 | SEC filing · Form 8-K | SEC EDGAR | +0.08% | +0.00% | |
| ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Revance Therapeutics, Inc. | Press release | PR Newswire | +0.00% | +0.15% | |
| BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Revance Therapeutics, Inc. (Nasdaq – RVNC), Greenbrook TMS, Inc. (OTC – GBNHF), R1 RCM Inc. (Nasdaq - RCM), Enstar Group Limited (Nasdaq – ESGR) | Press release | GlobeNewswire | -0.06% | +0.30% | |
| Crown Laboratories and Revance Announce Entry Into Merger Agreement | Press release | PR Newswire | -0.23% | +0.76% | |
| Form 8-K Revance Therapeutics, For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | -0.23% | +0.76% | |
| RVNC Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Revance Therapeutics to Crown Laboratories | Press release | GlobeNewswire | -0.08% | +0.92% | |
| RVNC Investigation: Halper Sadeh LLC Is Investigating Whether the Sale of Revance Therapeutics, Inc. Is Fair to Shareholders | Press release | Business Wire | +0.46% | +0.76% | |
| Form 8-K Revance Therapeutics, For: Aug 08 | SEC filing · Form 8-K | SEC EDGAR | +10.97% | +13.87% | |
| Form 10-Q Revance Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +10.97% | +13.87% | |
| Form 8-K Revance Therapeutics, For: Aug 08 | SEC filing · Form 8-K | SEC EDGAR | +10.97% | +13.87% | |
| Revance Reports Second Quarter 2024 Financial Results, Provides Corporate Update | Press release | Business Wire | +10.97% | +13.87% | |
| Revance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024 | Press release | Business Wire | -3.40% | -5.33% | |
| Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +0.71% | +0.00% | |
| Revance to Participate in Upcoming Investor Conferences | Press release | Business Wire | -1.12% | +4.48% | |
| Form 10-Q Revance Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -9.88% | -18.02% | |
| Form 8-K Revance Therapeutics, For: May 09 | SEC filing · Form 8-K | SEC EDGAR | -9.88% | -18.02% | |
| Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia | Press release | Business Wire | -9.88% | -18.02% | |
| Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update | Press release | Business Wire | -9.88% | -18.02% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RVNC section they belong to.
Where else RVNC is measured.
RVNC earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| PishPosh, Inc. (BABY) | 702 | 0.00% | 48% |
| Insmed Incorporated (INSM) | 701 | -0.08% | 45% |
| AB Corporate Bond ETF (EYEG) | 700 | 0.00% | 44% |
| STEMLINE THERAPEUTICS (STML) | 697 | +0.08% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Revance Therapeutics, Inc.'s median reaction calculated?
Every labeled RVNC news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 701 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 42% of RVNC's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RVNC's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.